Cargando…
Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial
AIMS: This analysis evaluated HbA(1c)-adjusted hypoglycemia risk with glargine versus neutral protamine Hagedorn (NPH) over a 5-year study in patients with Type 2 diabetes mellitus (T2DM). Clinical significance was assessed using number needed to harm (NNH) to demonstrate the risk of one additional...
Autores principales: | Rosenstock, Julio, Fonseca, Vivian, Schinzel, Stefan, Dain, Marie-Paule, Mullins, Peter, Riddle, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802045/ https://www.ncbi.nlm.nih.gov/pubmed/24856612 http://dx.doi.org/10.1016/j.jdiacomp.2014.04.003 |
Ejemplares similares
-
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus
NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012) -
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009) -
CCNO mutations in NPH?
por: Núnez-Ollé, Marc, et al.
Publicado: (2018) -
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009) -
iNPH—the mystery resolving
por: Leinonen, Ville, et al.
Publicado: (2021)